JP2023503472A - 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 - Google Patents

長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 Download PDF

Info

Publication number
JP2023503472A
JP2023503472A JP2022530716A JP2022530716A JP2023503472A JP 2023503472 A JP2023503472 A JP 2023503472A JP 2022530716 A JP2022530716 A JP 2022530716A JP 2022530716 A JP2022530716 A JP 2022530716A JP 2023503472 A JP2023503472 A JP 2023503472A
Authority
JP
Japan
Prior art keywords
gdf15
amino acid
seq
acting
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503472A5 (https=
Inventor
イム，セヨン
パク，ヨンボン
キム，スギョン
シム，ボラ
チョン，ウォニ
チェ・ヒョンホ
ヤン，ジウン
チュ，ミギョン
キム，ウォンテ
イ，ヨンウ
キム，ジュンファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2023503472A publication Critical patent/JP2023503472A/ja
Publication of JP2023503472A5 publication Critical patent/JP2023503472A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022530716A 2019-11-26 2020-11-25 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 Pending JP2023503472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0153680 2019-11-26
KR20190153680 2019-11-26
PCT/KR2020/016842 WO2021107603A2 (en) 2019-11-26 2020-11-25 Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
JP2023503472A true JP2023503472A (ja) 2023-01-30
JP2023503472A5 JP2023503472A5 (https=) 2023-12-04

Family

ID=76130664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530716A Pending JP2023503472A (ja) 2019-11-26 2020-11-25 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物

Country Status (11)

Country Link
US (1) US20230002460A1 (https=)
EP (1) EP4065597A4 (https=)
JP (1) JP2023503472A (https=)
KR (1) KR20210065057A (https=)
CN (1) CN114729020A (https=)
AU (1) AU2020394255A1 (https=)
BR (1) BR112022010227A2 (https=)
CA (1) CA3161302A1 (https=)
MX (1) MX2022006173A (https=)
WO (1) WO2021107603A2 (https=)
ZA (1) ZA202204624B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
US20240391971A1 (en) * 2021-08-24 2024-11-28 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CN120530128A (zh) * 2022-11-18 2025-08-22 株式会社柳韩洋行 双功能蛋白及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511752A (ja) * 2013-01-30 2016-04-21 エヌジーエム バイオファーマシューティカルズ インコー 代謝障害の処置における組成物及び使用方法
JP2017528419A (ja) * 2014-06-24 2017-09-28 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
JP2017533910A (ja) * 2014-10-30 2017-11-16 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ３５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
JP2017538395A (ja) * 2014-10-31 2017-12-28 エヌジーエム バイオファーマシューティカルズ インコー 代謝障害を処置するための組成物及びその使用方法
JP2019523637A (ja) * 2016-05-10 2019-08-29 ヤンセン バイオテツク，インコーポレーテツド Ｇｄｆ１５融合タンパク質及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
AU2015296640B2 (en) * 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511752A (ja) * 2013-01-30 2016-04-21 エヌジーエム バイオファーマシューティカルズ インコー 代謝障害の処置における組成物及び使用方法
JP2017528419A (ja) * 2014-06-24 2017-09-28 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
JP2017533910A (ja) * 2014-10-30 2017-11-16 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ３５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
JP2017538395A (ja) * 2014-10-31 2017-12-28 エヌジーエム バイオファーマシューティカルズ インコー 代謝障害を処置するための組成物及びその使用方法
JP2019523637A (ja) * 2016-05-10 2019-08-29 ヤンセン バイオテツク，インコーポレーテツド Ｇｄｆ１５融合タンパク質及びその使用

Also Published As

Publication number Publication date
CN114729020A (zh) 2022-07-08
EP4065597A4 (en) 2024-01-24
EP4065597A2 (en) 2022-10-05
CA3161302A1 (en) 2021-06-03
BR112022010227A2 (pt) 2022-09-13
WO2021107603A2 (en) 2021-06-03
AU2020394255A1 (en) 2022-06-09
US20230002460A1 (en) 2023-01-05
KR20210065057A (ko) 2021-06-03
WO2021107603A3 (en) 2021-07-15
MX2022006173A (es) 2022-06-14
ZA202204624B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
JP7303629B2 (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
JP2023503472A (ja) 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物
CN107286248B (zh) 高糖基化人生长激素融合蛋白及其制备方法与用途
JP7064618B2 (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
PT2697257T (pt) Proteínas de fusão fc compreendendo novos ligantes ou arranjos
CN104066845A (zh) 可溶性IGF受体Fc融合蛋白和其用途
US20180280474A1 (en) Treatment of bile acid disorders
KR102676582B1 (ko) 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
CN108727486A (zh) 长效神经生长因子、制备方法及其组合物
US20240238380A1 (en) Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
JP2021522231A (ja) チオエーテル環状ペプチドアミリン受容体調節因子
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
CN109328194B (zh) 包含ccl3变体的融合蛋白及其用途
RU2836280C1 (ru) Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция
US20240082354A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
HK40073215A (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2025252023A1 (en) Modulators for gipr, glp1r and/or gcgr and uses thereof
WO2024155803A2 (en) IgG Fc VARIANTS WITH REDUCED SELF-ASSOCIATION
HK40002751B (en) Fusion protein comprising ccl3 variant and use thereof
HK40002751A (en) Fusion protein comprising ccl3 variant and use thereof
NZ734482A (en) Fc fusion high affinity ige receptor α-chain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109